Vident Advisory LLC Invests $604,000 in QIAGEN N.V. $QGEN

Key Points

• Vident Advisory LLC has made a new investment in QIAGEN N.V., purchasing 15,040 shares valued at approximately $604,000 in the first quarter.
• Several hedge funds are modifying their holdings in QIAGEN, with 70% of the stock owned by institutional investors.
• QIAGEN reported its quarterly earnings meeting expectations with $0.60 EPS and a revenue of $533.54 million, marking a year-over-year revenue increase of 7.7%.

Vident Advisory LLC bought a new stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 15,040 shares of the company's stock, valued at approximately $604,000.

Several other institutional investors have also added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its stake in QIAGEN by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after buying an additional 2,204 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in QIAGEN by 3.0% during the 4th quarter. The Manufacturers Life Insurance Company now owns 96,482 shares of the company's stock valued at $4,322,000 after buying an additional 2,832 shares during the last quarter. AQR Capital Management LLC raised its stake in QIAGEN by 40.9% during the 4th quarter. AQR Capital Management LLC now owns 105,303 shares of the company's stock valued at $4,689,000 after buying an additional 30,571 shares during the last quarter. Ameriprise Financial Inc. raised its stake in QIAGEN by 66.3% during the 4th quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company's stock valued at $2,807,000 after buying an additional 25,134 shares during the last quarter. Finally, Cetera Investment Advisers raised its stake in QIAGEN by 14.4% during the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock valued at $505,000 after buying an additional 1,418 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

QIAGEN Price Performance

Shares of NYSE QGEN traded up $0.07 during midday trading on Monday, reaching $47.62. The stock had a trading volume of 885,116 shares, compared to its average volume of 1,332,689. The stock has a 50-day moving average of $48.65 and a 200-day moving average of $44.48. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of 28.13, a price-to-earnings-growth ratio of 2.51 and a beta of 0.64. QIAGEN N.V. has a 12-month low of $37.63 and a 12-month high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The company's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, research analysts anticipate that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Cowen reiterated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Wall Street Zen lowered shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Barclays started coverage on shares of QIAGEN in a research note on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target on the stock. Bank of America lifted their price target on shares of QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Finally, UBS Group lifted their price target on shares of QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, QIAGEN presently has a consensus rating of "Hold" and an average target price of $49.69.

QIAGEN Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.